4/21
11:45 am
ions
Rating for IONS
Low
Report
Rating for IONS
4/21
11:42 am
ions
Rating for IONS
Low
Report
Rating for IONS
4/21
11:42 am
ions
Rating for IONS
Low
Report
Rating for IONS
4/21
09:02 am
ions
Ionis Pharmaceuticals (IONS) had its "overweight" rating reaffirmed by Morgan Stanley.
Low
Report
Ionis Pharmaceuticals (IONS) had its "overweight" rating reaffirmed by Morgan Stanley.
4/21
09:02 am
ions
Ionis Pharmaceuticals (IONS) had its "overweight" rating reaffirmed by Morgan Stanley.
Low
Report
Ionis Pharmaceuticals (IONS) had its "overweight" rating reaffirmed by Morgan Stanley.
4/21
05:03 am
ions
Ionis Pharmaceuticals initiated with a Buy at Canaccord
Low
Report
Ionis Pharmaceuticals initiated with a Buy at Canaccord
4/20
04:21 pm
ions
Ionis Pharmaceuticals initiated with a Buy at Canaccord
Low
Report
Ionis Pharmaceuticals initiated with a Buy at Canaccord
3/26
08:43 am
ions
Rating for IONS
Low
Report
Rating for IONS
3/26
08:43 am
ions
Rating for IONS
Low
Report
Rating for IONS
3/25
11:28 am
ions
Rating for IONS
Low
Report
Rating for IONS
3/25
11:28 am
ions
Rating for IONS
Low
Report
Rating for IONS
3/3
11:11 am
ions
Rating for IONS
Low
Report
Rating for IONS
2/26
09:31 am
ions
Rating for IONS
Low
Report
Rating for IONS
2/26
06:16 am
ions
Rating for IONS
Low
Report
Rating for IONS
2/26
06:16 am
ions
Rating for IONS
Low
Report
Rating for IONS
2/25
03:58 pm
ions
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.
Low
Report
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.
2/25
03:58 pm
ions
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
2/25
03:58 pm
ions
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
1/28
08:03 am
ions
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
Low
Report
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.